CTLA4 and melanoma: By contrast, myositis/NMJ disorder [HR = 5.02, 95%CI (2.55; 9.87); P < 0.01], melanoma [compared to lung cancer, HR = 2.92, 95%CI (1.48; 5.74); P < 0.01], concomitant CTLA4 and PD(L)1 therapy [HR = 2.36, 95%CI (1.23; 4.51); P < 0.01], and presence of non-neurological irAEs [HR = 1.81, 95%CI (1.02; 3.24); P = 0.04] were associated with an increased rate of transition from severe to minor disability (Supplementary Fig. 6).